{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:07:48Z","timestamp":1784545668057,"version":"3.55.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016922","name":"MSD Italia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016922","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.dld.2019.01.018","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T09:49:18Z","timestamp":1549792158000},"page":"613-620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5128-3846","authenticated-orcid":false,"given":"Fabio Salvatore","family":"Macaluso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flaminia","family":"Cavallaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Felice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9479-5307","authenticated-orcid":false,"given":"Paolo","family":"Gionchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Vecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrogio","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2019.01.018_bib0005","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2019.01.018_bib0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.crohns.2014.08.012","article-title":"European evidence based consensus on surgery for ulcerative colitis","volume":"9","author":"\u00d8resland","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2019.01.018_bib0015","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.3748\/wjg.v18.i29.3833","article-title":"Role of surgery in severe ulcerative colitis in the era of medical rescue therapy","volume":"18","author":"Dayan","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2019.01.018_bib0020","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ecco-jcc\/jjv190","article-title":"Impact of new treatments on hospitalisation, surgery, infection, and mortality in IBD: a focus paper by the epidemiology committee of ECCO","volume":"10","author":"Annese","year":"2016","journal-title":"Crohns Colitis"},{"key":"10.1016\/j.dld.2019.01.018_bib0025","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/ibd.21654","article-title":"Pediatric inflammatory bowel disease: increasing incidence, decreasing surgery rate, and compromised nutritional status: a prospective population based cohort study 2007-2009","volume":"17","author":"Jakobsen","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2019.01.018_bib0030","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/j.1572-0241.2006.00552.x","article-title":"Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003\u20132005: a population-based study from the Danish Crohn colitis database","volume":"101","author":"Vind","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2019.01.018_bib0035","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ajg.2014.45","article-title":"Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy","volume":"109","author":"Vester-Andersen","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2019.01.018_bib0040","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1053\/j.gastro.2015.06.001","article-title":"Postoperative mortality among patients with inflammatory bowel diseases: a systematic review and meta-analysis of population-based studies","volume":"149","author":"Singh","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2019.01.018_bib0045","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/gutjnl-2013-304636","article-title":"Eastwest gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort","volume":"63","author":"Burisch","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2019.01.018_bib0050","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/j.gastro.2015.01.031","article-title":"SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease","volume":"148","author":"Laine","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2019.01.018_bib0055","doi-asserted-by":"crossref","first-page":"7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.dld.2019.01.018_bib0060","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cgh.2010.12.028","article-title":"Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis","volume":"9","author":"Ardizzone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2019.01.018_bib0065","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/gutjnl-2012-303864","article-title":"Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study","volume":"63","author":"Charpentier","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2019.01.018_bib0070","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1053\/j.gastro.2011.06.054","article-title":"Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis","volume":"141","author":"Colombel","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2019.01.018_bib0075","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/gut.51.6.803","article-title":"Effects of appendicectomy on the course of ulcerative colitis","volume":"51","author":"Cosnes","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.dld.2019.01.018_bib0080","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3109\/00365521.2015.1070900","article-title":"Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study)","volume":"51","author":"Fern\u00e1ndez-Salazar","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2019.01.018_bib0085","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00384-014-1850-x","article-title":"NOD2 gene mutations in ulcerative colitis: useless or misunderstood?","volume":"29","author":"Freire","year":"2014","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.dld.2019.01.018_bib0090","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/DCR.0b013e31819ad456","article-title":"Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis","volume":"52","author":"Hefti","year":"2009","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.dld.2019.01.018_bib0095","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1136\/gut.2007.146357","article-title":"C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study","volume":"57","author":"Henriksen","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.dld.2019.01.018_bib0100","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/MEG.0000000000000896","article-title":"Prevalence of intestinal complications in inflammatory bowel disease: a comparison between paediatric-onset and adult-onset patients","volume":"29","author":"Herzog","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2019.01.018_bib0105","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2036.2006.02974.x","article-title":"The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort","volume":"24","author":"Ho","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2019.01.018_bib0110","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1053\/j.gastro.2006.11.015","article-title":"Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years","volume":"132","author":"Hoie","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2019.01.018_bib0115","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10620-009-0749-9","article-title":"Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection","volume":"55","author":"Jodorkovsky","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2019.01.018_bib0120","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1007\/s10620-013-2828-1","article-title":"Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infliximab in patients with ulcerative colitis","volume":"58","author":"Park","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2019.01.018_bib0125","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3109\/00365521.2015.1019558","article-title":"Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study","volume":"50","author":"Christensen","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2019.01.018_bib0130","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/00365521.2016.1200141","article-title":"Low colectomy rate five years after diagnosis of ulcerative colitis. Results from a prospective population-based cohort in Sweden (ICURE) diagnosed during 2005-2009","volume":"51","author":"R\u00f6nnblom","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2019.01.018_bib0135","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.dld.2013.03.018","article-title":"Adalimumab in active ulcerative colitis: a \u201creal-life\u201d observational study","volume":"45","author":"Italian Group for the Study of Inflammatory Bowel Disease","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2019.01.018_bib0140","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/apt.13893","article-title":"Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients","volume":"45","author":"Angelison","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2019.01.018_bib0145","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/gut.51.6.808","article-title":"Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn\u2019s disease","volume":"51","author":"Radford-Smith","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.dld.2019.01.018_bib0150","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1365-2036.2010.04531.x","article-title":"Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab","volume":"33","author":"Taxonera","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2019.01.018_bib0155","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s11605-017-3530-y","article-title":"Incidence rates and predictors of colectomy for ulcerative colitis in the era of biologics: results from a provincial database","volume":"22","author":"Abou Khalil","year":"2018","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.dld.2019.01.018_bib0160","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/2050640615627533","article-title":"Risk factors for complications in patients with ulcerative colitis","volume":"4","author":"Manser","year":"2016","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.dld.2019.01.018_bib0165","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1097\/MIB.0000000000001117","article-title":"Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease","volume":"23","author":"Buhl","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.dld.2019.01.018_bib0170","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cgh.2014.07.055","article-title":"A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis","volume":"13","author":"Arias","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2019.01.018_bib0175","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/imj.12397","article-title":"Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy","volume":"44","author":"Subramaniam","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.dld.2019.01.018_bib0180","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1053\/j.gastro.2011.06.054","article-title":"Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis","volume":"141","author":"Colombel","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2019.01.018_bib0185","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/ibd.21932","article-title":"Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics","volume":"18","author":"Williet","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2019.01.018_bib0190","first-page":"1348","article-title":"Prevalence and risk factors for therapy escalation in ulcerative Colitis in the Swiss IBD Cohort Study","volume":"21","author":"Safroneeva","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2019.01.018_bib0195","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1007\/s10620-015-3735-4","article-title":"Infliximab dose escalation as an effective strategy for managing secondary loss of response in ulcerative colitis","volume":"60","author":"Taxonera","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2019.01.018_bib0200","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/ibd.20897","article-title":"Risk factors and characteristics of extent progression in ulcerative colitis","volume":"15","author":"Etchevers","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2019.01.018_bib0205","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.crohns.2012.10.004","article-title":"Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome","volume":"7","author":"Garc\u00eda-Bosch","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2019.01.018_bib0210","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.crohns.2008.03.004","article-title":"Long-term outcome after infliximab for refractory ulcerative colitis","volume":"2","author":"Ferrante","year":"2008","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2019.01.018_bib0215","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1365-2036.2007.03300.x","article-title":"Infliximab for the treatment of ulcerative colitis: outcomes in Oxfordfrom 2000 to 2006","volume":"25","author":"Jakobovits","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2019.01.018_bib0220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5152\/tjg.2015.5071","article-title":"Clinical course and predictors of total colectomy in ulcerative colitis; a referral center experience from Turkey","volume":"26","author":"Kalkan","year":"2015","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.dld.2019.01.018_bib0225","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/apt.12834","article-title":"Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe long-term course of the disease \u2014 a nationwide study of 1035 patients","volume":"40","author":"Khan","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2019.01.018_bib0230","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/MIB.0b013e3182802b3e","article-title":"Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort","volume":"19","author":"Lakatos","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2019.01.018_bib0235","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10620-013-2908-2","article-title":"Racial and ethnic differences in health care utilization and outcomes among ulcerative colitis patients in an integrated health-care organization","volume":"59","author":"Li","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2019.01.018_bib0240","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1097\/MIB.0000000000000787","article-title":"Disease course and colectomy rate of ulcerative colitis: a follow-up cohort study of a referral center in Tuscany","volume":"22","author":"Manetti","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2019.01.018_bib0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074861","article-title":"Serum glycan markers for evaluation of disease activity and prediction of clinical course in patients with ulcerative colitis","volume":"8","author":"Miyahara","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2019.01.018_bib0250","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1038\/ajg.2010.345","article-title":"A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization","volume":"105","author":"Oussalah","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2019.01.018_bib0255","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ajg.2008.38","article-title":"Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease","volume":"104","author":"Romberg-Camps","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2019.01.018_bib0260","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1136\/gutjnl-2013-305607","article-title":"Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011","volume":"63","author":"Rungoe","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2019.01.018_bib0265","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/2050640616679552","article-title":"Risk factors for proximal disease extension and colectomy in left-sided ulcerative colitis","volume":"5","author":"Sahami","year":"2017","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.dld.2019.01.018_bib0270","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000229773","article-title":"What determines the later clinical course of patients who do not undergo colectomy at the first attack? A Japanese cohort study on ulcerative colitis","volume":"81","author":"Shiga","year":"2010","journal-title":"Digestion"},{"key":"10.1016\/j.dld.2019.01.018_bib0275","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10620-016-4398-5","article-title":"Adalimumab maintenance treatment in ulcerative colitis: outcomes by prior anti-TNF use and efficacy of dose escalation","volume":"62","author":"Taxonera","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2019.01.018_bib0280","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s00535-016-1274-1","article-title":"Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-na\u00e9ve and non-na\u00e9ve patients","volume":"52","author":"Iborra","year":"2017","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.dld.2019.01.018_bib0285","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ibd.20639","article-title":"History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis","volume":"15","author":"Ananthakrishnan","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2019.01.018_bib0290","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/ibd.20884","article-title":"Effects of active and passive smoking on disease course of Crohn\u2019s disease and ulcerative colitis","volume":"15","author":"van der Heide","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2019.01.018_bib0295","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1097\/MIB.0000000000001211","article-title":"Clinical predictors of the risk of early colectomy in ulcerative colitis: a population-based study","volume":"23","author":"Al-Darmaki","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2019.01.018_bib0300","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/MIB.0000000000001144","article-title":"Clinical outcomes of golimumab as first, second or third anti-TNF agent in patients with moderate-to-severe ulcerative colitis","volume":"23","author":"Taxonera","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2019.01.018_bib0305","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/ibd.21119","article-title":"Ulcerative colitis in a Southern European country: a national perspective","volume":"16","author":"Portela","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2019.01.018_bib0310","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/jgh.12967","article-title":"Prospective population-based cohort of inflammatory bowel disease in the biologics era: disease course and predictors of severity","volume":"30","author":"Niewiadomski","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2019.01.018_bib0315","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/jgh.12661","article-title":"Serological markers associated with disease behavior and response to anti-tumor necrosis factor therapy in ulcerative colitis","volume":"30","author":"Kevans","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2019.01.018_bib0320","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/ecco-jcc\/jjx066","article-title":"Proximal disease extension in patients with limited ulcerative colitis: a Danish population-based inception cohort","volume":"11","author":"Burisch","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2019.01.018_bib0325","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1097\/MIB.0000000000000115","article-title":"Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis","volume":"20","author":"Armuzzi","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2019.01.018_bib0330","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.crohns.2014.03.014","article-title":"Risk of colectomy in patients with ulcerative colitis under thiopurine treatment","volume":"8","author":"Ca\u00f1as-Ventura","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2019.01.018_bib0335","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/MIB.0b013e3182802909","article-title":"Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission","volume":"19","author":"Armuzzi","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2019.01.018_bib0340","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1038\/ajg.2010.345","article-title":"A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization","volume":"105","author":"Oussalah","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2019.01.018_bib0345","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s11605-017-3431-0","article-title":"As infliximab use for ulcerative colitis has increased, so has the rate of surgical resection","volume":"21","author":"Kin","year":"2017","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.dld.2019.01.018_bib0350","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/MEG.0b013e32833036d9","volume":"22","author":"Szamosi","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2019.01.018_bib0355","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s10620-016-4089-2","article-title":"Long-term follow-up of patients treated with infliximab for ulcerative colitis: predictive factors of response \u2014 an observational study","volume":"61","author":"Garc\u00eda-Bosch","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2019.01.018_bib0360","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/apt.13017","article-title":"The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989 and 2009","volume":"41","author":"Chhaya","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2019.01.018_bib0365","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.3109\/00365521.2015.1064991","article-title":"Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study)","volume":"50","author":"Solberg","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2019.01.018_bib0370","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1097\/MIB.0000000000000474","article-title":"Extent of early clinical response to infliximab predicts long-term treatment success in active ulcerative colitis","volume":"21","author":"Murthy","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2019.01.018_bib0375","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/ecco-jcc\/jjw067","article-title":"Long-term outcome of patients with ulcerative colitis and primary non-response to infliximab","volume":"10","author":"Papamichael","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2019.01.018_bib0380","first-page":"527","article-title":"Frequency, predictors, and consequences of maintenance infliximab therapy intensification in ulcerative colitis","volume":"107","author":"Fern\u00e1ndez-Salazar","year":"2015","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.dld.2019.01.018_bib0385","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.dld.2013.10.007","article-title":"Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study","volume":"46","author":"Cesarini","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2019.01.018_bib0390","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1365-2036.2011.04986.x","article-title":"Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis","volume":"35","author":"Rostholder","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2019.01.018_bib0395","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/apt.12289","article-title":"Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience","volume":"37","author":"Laharie","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2019.01.018_bib0400","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/ajg.2017.183","article-title":"Appendectomy and the risk of colectomy in ulcerative colitis: a national cohort study","volume":"112","author":"Myrelid","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2019.01.018_bib0405","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1136\/gutjnl-2016-311550","article-title":"Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis","volume":"66","author":"Parian","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.dld.2019.01.018_bib0410","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2019.01.018_bib0415","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/14737140.2017.1392243","article-title":"Screening of colorectal cancer: present and future","volume":"17","author":"Maida","year":"2017","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865819300532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865819300532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:10:43Z","timestamp":1761624643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865819300532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1590865819300532"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2019.01.018","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2019.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}